Pfizer announced last week that it is discontinuing development of its twice-daily weight loss pill "danuglipron" after a clinical trial showed "high rates" of adverse side effects among users.
A study published in Scientific Reports found that females and young adults had greater risks of "general fatigue, headache, joint pain, chills and axillary pain compared to males and elderly adults."
In a recent move to address concerns about post-vaccination deaths, South Korean officials have boosted the condolence money offered to affected families.
